Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A novel scoring system for pivotal autophagy-related genes predicts outcomes after chemotherapy in advanced ovarian cancer patients.

Niu Y, Sun W, Chen K, Fu Z, Chen Y, Zhu J, Chen H, Shi Y, Zhang H, Wang L, Shen HM, Xia D, Wu Y.

Cancer Epidemiol Biomarkers Prev. 2019 Sep 18. pii: cebp.0359.2019. doi: 10.1158/1055-9965.EPI-19-0359. [Epub ahead of print]

PMID:
31533939
2.

A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.

Kang J, D'Andrea AD, Kozono D.

J Natl Cancer Inst. 2012 May 2;104(9):670-81. doi: 10.1093/jnci/djs177. Epub 2012 Apr 13.

3.

Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer.

Lu J, Wu D, Li C, Zhou M, Hao D.

J Mol Med (Berl). 2014 Nov;92(11):1159-68. doi: 10.1007/s00109-014-1191-9. Epub 2014 Jul 27.

PMID:
25062964
4.

Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.

Hillman RT, Chisholm GB, Lu KH, Futreal PA.

J Natl Cancer Inst. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx176.

5.
6.

Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.

An Y, Bi F, You Y, Liu X, Yang Q.

J Cancer. 2018 Oct 18;9(21):4058-4071. doi: 10.7150/jca.25587. eCollection 2018.

7.

4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.

Liu M, Bamodu OA, Huang WC, Zucha MA, Lin YK, Wu ATH, Huang CC, Lee WH, Yuan CC, Hsiao M, Deng L, Tzeng YM, Yeh CT.

Toxicol Appl Pharmacol. 2017 Jun 15;325:48-60. doi: 10.1016/j.taap.2017.04.003. Epub 2017 Apr 10.

PMID:
28408137
8.

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.

Miller KR, Patel JN, Zhang Q, Norris EJ, Symanowski J, Michener C, Sehouli J, Braicu I, Destephanis DD, Sutker AP, Jones W, Livasy CA, Biscotti C, Ganapathi RN, Tait DL, Ganapathi MK.

Gynecol Oncol. 2018 Apr;149(1):155-162. doi: 10.1016/j.ygyno.2018.01.022.

PMID:
29402501
9.

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W.

J Natl Cancer Inst. 2015 May 20;107(7). pii: djv108. doi: 10.1093/jnci/djv108. Print 2015 Jul. Erratum in: J Natl Cancer Inst. 2017 Nov 1;109(11):.

10.

Establishment of a 12-gene expression signature to predict colon cancer prognosis.

Sun D, Chen J, Liu L, Zhao G, Dong P, Wu B, Wang J, Dong L.

PeerJ. 2018 Jun 14;6:e4942. doi: 10.7717/peerj.4942. eCollection 2018.

11.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J.

J Clin Oncol. 2013 Apr 20;31(12):1554-61. doi: 10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.

12.

Wnt Signaling and Survival of Women With High-Grade Serous Ovarian Cancer: A Brief Report.

Seagle BL, Dandapani M, Yeh JY, Shahabi S.

Int J Gynecol Cancer. 2016 Jul;26(6):1078-1080. doi: 10.1097/IGC.0000000000000726.

PMID:
30814169
13.

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.

van Baal JOAM, Van de Vijver KK, Algera MD, van der Aa MA, Sonke GS, van Driel WJ, Kenter GG, Amant FC, Lok CAR.

Gynecol Oncol. 2019 Jun;153(3):562-567. doi: 10.1016/j.ygyno.2019.03.257. Epub 2019 Apr 1.

PMID:
30948193
14.

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).

Chung YS, Park SY, Lee JY, Park JY, Lee JW, Kim HS, Suh DS, Kim YH, Lee JM, Kim M, Choi MC, Shim SH, Lee KH, Song T, Hong JH, Lee WM, Lee B, Lee IH.

BMC Cancer. 2019 Apr 11;19(1):341. doi: 10.1186/s12885-019-5514-7.

15.

Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.

Gao Y, Liu X, Li T, Wei L, Yang A, Lu Y, Zhang J, Li L, Wang S, Yin F.

Oncol Rep. 2017 May;37(5):3084-3092. doi: 10.3892/or.2017.5534. Epub 2017 Mar 27.

PMID:
28350120
16.

Reducing confounding and suppression effects in TCGA data: an integrated analysis of chemotherapy response in ovarian cancer.

Hsu FH, Serpedin E, Hsiao TH, Bishop AJ, Dougherty ER, Chen Y.

BMC Genomics. 2012;13 Suppl 6:S13. doi: 10.1186/1471-2164-13-S6-S13. Epub 2012 Oct 26.

17.

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.

J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29.

PMID:
26124480
18.

Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro.

Correa RJ, Valdes YR, Shepherd TG, DiMattia GE.

J Ovarian Res. 2015 Aug 4;8:52. doi: 10.1186/s13048-015-0182-y.

19.

Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.

Murakami R, Matsumura N, Brown JB, Wang Z, Yamaguchi K, Abiko K, Yoshioka Y, Hamanishi J, Baba T, Koshiyama M, Mandai M, Yamada R, Konishi I.

Gynecol Oncol. 2016 Apr;141(1):49-56. doi: 10.1016/j.ygyno.2016.02.027.

PMID:
27016229
20.

HSP60 predicts survival in advanced serous ovarian cancer.

Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Shoshan M, Avall-Lundqvist E.

Int J Gynecol Cancer. 2013 Mar;23(3):448-55. doi: 10.1097/IGC.0b013e318284308b.

PMID:
23429486

Supplemental Content

Support Center